Originally Posted by
common cents
Blackout don’t waste your time with the likes of 43Inches.
If you want to get a handle of the real nature of this Covid problem then have a look at this real world data
All persons who were newly vaccinated during the period from December 20, 2020, to February 1, 2021, were matched to unvaccinated controls in a 1:1 ratio according to demographic and clinical characteristics.
As you can see the vaccines are having an effect on case numbers and fatality rates. But the intent of my post is to try and extrapolate the real nature of the Covid problem.
Two cohorts of 596 618 people each followed out to 42 days.
Infections in Unvaccinated 29365 Fatalities 112 .....IFR 0.38%
Infections in vaccinated 22943 Fatalities 32 ...........IFR 0.14%
Put in another way recovery rate in Unvaccinated was 99.62% and in Vaccinated was 99.86%
These IFR are similar to Stanford University modelling. The difference is the above data is Real World.
Here's the abstract for the paper the you've taken that graphic from.
BACKGROUND
As mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse populations in a noncontrolled setting. In this study, data from Israel’s largest health care organization were used to evaluate the effectiveness of the BNT162b2 mRNA vaccine.
METHODS
All persons who were newly vaccinated during the period from December 20, 2020, to February 1, 2021, were matched to unvaccinated controls in a 1:1 ratio according to demographic and clinical characteristics. Study outcomes included documented infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), symptomatic Covid-19, Covid-19–related hospitalization, severe illness, and death. We estimated vaccine effectiveness for each outcome as one minus the risk ratio, using the Kaplan–Meier estimator.
RESULTS
Each study group included 596,618 persons. Estimated vaccine effectiveness for the study outcomes at days 14 through 20 after the first dose and at 7 or more days after the second dose was as follows: for documented infection, 46% (95% confidence interval [CI], 40 to 51) and 92% (95% CI, 88 to 95); for symptomatic Covid-19, 57% (95% CI, 50 to 63) and 94% (95% CI, 87 to 98); for hospitalization, 74% (95% CI, 56 to 86) and 87% (95% CI, 55 to 100); and for severe disease, 62% (95% CI, 39 to 80) and 92% (95% CI, 75 to 100), respectively. Estimated effectiveness in preventing death from Covid-19 was 72% (95% CI, 19 to 100) for days 14 through 20 after the first dose. Estimated effectiveness in specific subpopulations assessed for documented infection and symptomatic Covid-19 was consistent across age groups, with potentially slightly lower effectiveness in persons with multiple coexisting conditions.
CONCLUSIONS
This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19–related outcomes, a finding consistent with that of the randomized trial.
BNT162b2 is BioNTech Pfizer.
The authors of that
study (
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting, Dagan
et al) found vaccine effectiveness at the important efficacy endpoints of preventing hospitalisation and severe illness 7 or more days after the second dose were 87% for hospitalization, and 92% for severe disease. The estimated effectiveness in preventing death after the first dose was 72%.